Latest Advances in Lung Cancer Research

Researchers developed a test detecting proteins in blood that indicate lung cancer spread, promising for early metastasis detection and treatment guidance.

Johnson & Johnson’s Rybrevant shows comparable efficacy to AstraZeneca’s Tagrisso in advanced NSCLC, suggesting potential as an initial treatment option.

Experimental gene therapy drug HPN328 is being tested with Tecentriq in a trial to enhance immune response against small cell lung cancer.

This study assessed real-world survival among older patients with non–small-cell lung cancer (NSCLC) and brain metastases (BMs) at diagnosis receiving first-line immune checkpoint inhibitors (ICIs) compared with chemotherapy only.

Adding atezolizumab and tiragolumab to chemotherapy may improve survival in extensive stage small cell lung cancer, with further research needed.

Early onset of menstruation and menopause may increase women’s lung cancer risk, suggesting a possible hormonal influence; further research is needed.

Fred Hutchinson Cancer Center received a $30 million NCI grant to enhance cancer research and support vital services for the next five years.

Study indicates advanced lung cancer patients may stop immunotherapy after 2 years without impacting survival, requiring further research for confirmation.

Adagrasib shows promise in treating KRAS G12C-mutant NSCLC, with lasting responses and potential as a much-needed targeted therapy.

Study reveals 1 in 12 advanced lung cancer patients died from COVID-19 during the Omicron wave, highlighting the variant’s significant risk despite lower severity.

At 22, Leah Hubbard faces advanced lung cancer potentially linked to teenage pregnancy, challenging assumptions about the disease and raising awareness.

At the 2023 World Conference, lung cancer advocacy triumphed with a 25% funding boost for the Lung Cancer Research Program, thanks to strategic lobbying and a unified advocacy platform.